Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   85 Trials   85 Trials   3645 News 


«12...34353637383940414243444546»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. (Pubmed Central) -  Nov 29, 2018   
    Antibody-drug conjugates such as inotuzumab ozogamicin and the bispecific T-cell engager blinatumomab represent novel antibody constructs that have shown substantial clinical activity in ALL. Although most studies have focused on the use of these agents in the salvage setting, incorporation of these antibodies into the frontline regimens is imperative to improve long-term survival for patients with ALL and to increase the cure rates of adult ALL to the levels achieved in the pediatric population.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment change, Trial completion date, Trial primary completion date, Minimal residual disease:  Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 31, 2018   
    P2,  N=60, Recruiting, 
    Trial completion date: Jan 2020 --> May 2020 | Trial primary completion date: Jan 2020 --> May 2020 N=30 --> 60 | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jul 2018 --> Jul 2020
  • ||||||||||  Scemblix (asciminib) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment open, Combination therapy:  ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (clinicaltrials.gov) -  Oct 16, 2018   
    P1,  N=34, Recruiting, 
    Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Mar 2021 --> Jul 2020 Not yet recruiting --> Recruiting
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Redirecting T cells to hematological malignancies with bispecific antibodies. (Pubmed Central) -  Oct 13, 2018   
    Nevertheless, the success of blinatumomab has reinvigorated the BsAb field, which is bustling with preclinical and clinical studies not only for B-cell derived lymphoblastic leukemia and lymphoma, but also for acute myeloid leukemia and multiple myeloma. Here we will review successes and challenges of T-cell targeted BsAbs for the immunotherapy of hematological malignancies with special focus on conducted clinical studies and strategies to improve their efficacy.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. (Pubmed Central) -  Oct 12, 2018   
    For less fit patients with Ph-positive ALL, the use of TK inhibitors with reduced-intensity chemotherapy or steroids alone results in high rates of remission, but, without further consolidation, relapses are inevitable. Many novel targeted and immunotherapeutic agents are being developed, offering more effective and tolerable treatment options.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Review, Journal:  Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children. (Pubmed Central) -  Jul 27, 2018   
    In recent years, novel immune-based therapies have been developed that have shown impressive results and that have the potential to improve the outcome of relapsed ALL. These include antibody-drug conjugates, the bispecific T-cell-engaging antibody blinatumomab, and chimeric antigen receptor-modified T cells.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment open, Minimal residual disease:  PETHEMA-BLIN-01/PET069014 (BLIN-01) (clinicaltrials.gov) -  Jul 27, 2018   
    P2,  N=38, Recruiting, 
    These include antibody-drug conjugates, the bispecific T-cell-engaging antibody blinatumomab, and chimeric antigen receptor-modified T cells. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal, IO biomarker:  Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. (Pubmed Central) -  Jul 11, 2018   
    We also discuss the front-line management of primary mediastinal large cell lymphoma using the EPOCH (etoposide, prednisolone, Oncovin [vincristine], cyclophosphamide, hydroxydaunorubicin [doxorubicin]) regimen and examine new salvage data on immune checkpoint inhibitors for this clinical subtype...The most popular salvage regimens and the application of high-dose chemotherapy with stem cell transplantation are assessed in detail. Finally, data on new treatment tactics such as CART (chimeric antigen receptor T-cell) cells and promising new drugs, including blinatumomab and venetoclax, are presented.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    New P2 trial, Minimal residual disease:  PETHEMA-BLIN-01/PET069014 (BLIN-01) (clinicaltrials.gov) -  May 16, 2018   
    P2,  N=38, Not yet recruiting, 
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab. (Pubmed Central) -  May 15, 2018   
    Despite blinatumomab's relatively modest myelosuppression and the lack of mucotoxicity, host factors (e.g., duration and degree of neutropenia/lymphopenia) play a key role and should be considered when choosing anti-microbial prophylaxis. In relapsed/refractory disease, the ANC should be monitored closely post blinatumomab since neutropenia can unexpectedly develop after treatment which may be compounded by the underlying disease and recent chemotherapy effects.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Phase classification:  Observational Study of Blinatumomab (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=360, Recruiting, 
    Not yet recruiting --> Recruiting Phase classification: P=N/A --> P